CD274 and sarcoma: In the immunogenic MCA205 mouse sarcoma model, dosing of 200 mg/kg BLU7482 daily led to enhanced antitumor activity in combination with anti–PD-L1 compared with anti–PD-L1 alone (Figure 6).